March 14, 2011
In early-stage study results reported recently to investors, Gilead Sciences Inc. said its four-drug combination eliminated hepatitis C virus in patients. The trial examined the use of Gilead GS-9256 and GS-9190 with the standard drugs ribavirin and peginterferon. The researchers plan to present their findings at the annual meeting of the European Association for the Study of the Liver, which begins March 30 in Berlin.
No comments have been made.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.
|Conversations With Federal HIV Leaders From the 2017 U.S. Conference on AIDS|
|DACA, Immigrant Rights and the 'Larger Compassion' of the HIV Community|
|This Week in HIV Research: Injectable PrEP Shows Promise in New Study|
|Heavy Marijuana Use Tied to Midlife Cardiovascular Events in U.S. Men With HIV|
|Conversations on Viral Suppression and HIV Transmission, Social Media and HIV, and an Update on PACHA From the 2017 U.S. Conference on AIDS|
|Guidance for Providers Treating HIV-Positive People Displaced by Hurricane Harvey|